Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial of Everolimus (RAD001) in Relapsed/Refractory Lymphoma

Trial Profile

Phase II Trial of Everolimus (RAD001) in Relapsed/Refractory Lymphoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Nov 2018

At a glance

  • Drugs Everolimus (Primary)
  • Indications Leukaemia; Lymphoma; Lymphoproliferative disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Oct 2018 Planned End Date changed from 1 Jan 2015 to 1 Dec 2020.
    • 16 Oct 2018 Status has been changed to active, no longer recruiting.
    • 07 Jun 2016 Results of two completed phase II trials (NCT00436618 and NCT00918333) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top